Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target remains the same with $138.00.
Akash Tewari has given his Buy rating due to a combination of factors surrounding Merck & Company’s recent developments. The Phase 3 ZENITH trial results for Winrevair were particularly compelling, showing a significant reduction in the relative risk of major morbidity and mortality events compared to placebo. This strong efficacy, demonstrated by a hazard ratio of 0.24, indicates a promising outlook for the drug’s market potential.
Moreover, the safety profile of Winrevair appears manageable, with lower rates of serious adverse events compared to placebo. The potential for Winrevair to be used earlier in the treatment paradigm and its ability to reduce the need for background PAH treatments further enhances its appeal. Additionally, the possibility of expanding Winrevair’s label in the European market could drive broader adoption, supporting a positive long-term growth trajectory for Merck. These factors collectively underpin Tewari’s optimistic view and Buy rating on Merck’s stock.
In another report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $113.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock.